The earnings call highlighted DaVita's robust financial performance, resilience during natural disruptions, and reaffirmed guidance for 2024. However, challenges such as supply chain disruptions, continued elevated mortality, and increased operational costs were noted. DaVita's strategic efforts in debt management and share repurchases were positive, but the uncertainty around future interest expenses and advocacy costs remains.

Company Guidance

During DaVita's Q3 2024 earnings call, several key metrics and guidance updates were provided. The company reaffirmed its 2024 adjusted operating income guidance of $1.91 billion to $2.01 billion, despite anticipating a $10 million to $20 million impact in Q4 due to hurricane-related supply chain disruptions. DaVita reported Q3 adjusted operating income of $535 million and adjusted earnings per share of $2.59. The company achieved strong cash flow, with free cash flow at $555 million. While treatment volume growth remains challenged, DaVita still projects full-year growth of 0.5% to 1%. The call also highlighted ongoing challenges related to elevated mortality rates and supply chain issues, particularly with Baxter's PD solutions. Looking ahead, DaVita expects adjusted OI growth to return to pre-pandemic levels, with formal 2025 guidance to be provided next quarter.

Resilience During Hurricane Disruptions

Despite the impact of Hurricanes Helene and Milton, DaVita's operations were largely resilient with most centers reopening quickly. The company managed supply chain disruptions effectively, ensuring continued patient care.

Strong Financial Performance

Adjusted operating income for Q3 was $535 million, with an adjusted EPS of $2.59 and strong free cash flow of $555 million.

Reaffirmed Guidance

DaVita reaffirmed its 2024 guidance with adjusted operating income between $1.91 billion and $2.01 billion, and adjusted EPS of $9.25 to $10.05.

Successful Capital Strategy

The company successfully completed two debt transactions totaling $2.1 billion, lowering their nearest debt maturity to 2028, and repurchased 2.7 million shares in Q3.

Integrated Kidney Care Growth

Integrated Kidney Care segment showed a $32 million sequential increase due to operational efficiencies and revenue recognition timing.

---

DaVita (DVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 18, 2025	2024 (Q4)	2.14 / -	1.87	―	―	―
Oct 29, 2024	2024 (Q3)	2.72 / 2.59	2.85	-9.12% (-0.26)	―
Aug 06, 2024	2024 (Q2)	2.59 / 2.59	2.08	24.52% (+0.51)	―
May 02, 2024	2024 (Q1)	1.95 / 2.38	1.58	50.63% (+0.80)	―
Feb 13, 2024	2023 (Q4)	1.63 / 1.87	1.11	68.47% (+0.76)	―
Nov 07, 2023	2023 (Q3)	2.01 / 2.85	1.45	96.55% (+1.40)	―
Aug 03, 2023	2023 (Q2)	1.71 / 2.08	2.3	-9.57% (-0.22)	―
May 08, 2023	2023 (Q1)	1.18 / 1.58	1.61	-1.86% (-0.03)	―
Feb 22, 2023	2022 (Q4)	0.93 / 1.11	2.02	-45.05% (-0.91)	―
Oct 28, 2022	2022 (Q3)	1.77 / 1.45	2.36	-38.56% (-0.91)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

DVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 29, 2024	$158.31	$141.22	-10.80%
Aug 06, 2024	$136.99	$133.98	-2.20%
May 02, 2024	$142.24	$134.45	-5.48%
Feb 13, 2024	$113.60	$123.41	+8.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---